SynthesisFrontiers in nutrition2025
Prognostic value of sarcopenia in aortic valve replacement: a systematic review and meta-analysis.
Synthesis in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to quantify the prevalence of sarcopenia in patients undergoing surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR), and to assess its association with mortality risk. Methods: Relevant studies were identified through searches of the PubMed, Cochrane Library, Excerpta Medica Database (Embase), Web of Science, and China National Knowledge Infrastructure (CNKI) from inception through July 1, 2025. The prevalence of sarcopenia and its 95% confidence interval (CI) were calculated, with heterogeneity evaluated using the Results: Thirty-eight studies were included, with 6 focusing on patients undergoing SAVR and 32 on those undergoing TAVR. Sarcopenia was defined by skeletal mass index in 16 studies, while only 2 studies adopted criteria combining reduced muscle mass with low muscle strength and/or reduced physical performance. Sarcopenia's prevalence among SAVR patients was 31.3% (95% CI 25.3-37.6%). In this cohort, sarcopenia was linked to a significantly higher risk of long-term (≥1 year) mortality (HR = 3.10, 95% CI 2.00-4.79, Conclusion: Despite the variation in diagnostic criteria, sarcopenia is significantly prevalent in both SAVR and TAVR populations, with a clear association with elevated long-term mortality following these procedures. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024606633.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.